NCT07288203Phase 2Active not recruiting

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Study sponsor: Iovance Biotherapeutics, Inc. · IOVA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants24Estimated
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Description: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC Time frame: 5 years. After: Measure: Objective Response Rate Description: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators Time frame: 12 months.

Planned enrollment decreased by 76 participants

Before: 100 participants (planned). After: 24 participants (planned).

Primary completion date changed

Before: Dec 2032. After: Dec 2027.

Check registry source

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source